Boundless Bio, Inc. (BOLD)

Market Cap	25.52M -42.8%
Revenue (ttm)	n/a
Net Income	-58.20M
EPS	-2.60
Shares Out	22.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,097
Open	1.150
Previous Close	1.130
Day's Range	1.120 - 1.150
52-Week Range	0.961 - 1.790
Beta	-0.21
Analysts	Strong Buy
Price Target	4.00 (+250.88%)
Earnings Date	Mar 9, 2026

About BOLD

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company’s lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2024
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLD
• Website: https://boundlessbio.com

Analyst Summary

According to 3 analysts, the average rating for BOLD stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 250.88% from the latest price.

Price Target

$4.0

(250.88% upside)

Analyst Consensus: Strong Buy